LSKL TFA
LSKL TFA is a blood-brain barrier permeable TGF-β1 antagonist derived from LAP. It functions by inhibiting the TSP-1/LAP interaction, thereby blocking TGF-β1 activation. This mechanism has demonstrated efficacy in preclinical models of subarachnoid hemorrhage, renal fibrosis, and liver fibrosis.
Product Specifications
Product Name Alternative
LSKL, Inhibitor of Thrombospondin (TSP 1) (TFA), LSKL, Inhibitor of Thrombospondin (TSP-1), LSKL, Inhibitor of Thrombospondin (TSP1) (TFA), LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA), H-Leu-Ser-Lys-Leu-NH2 TFA, H-Leu-Ser-Lys-Leu-NH2 TFA (283609-79-0 TFA), TGF-β1, TGF-β/Smad, TGF-β Receptor, TGFβ, TGFbeta/Smad, TGF-b/Smad, TGFb, TGFbeta, TGF-beta, Smad
Field of Research
Immunology & Inflammation, Stem Cell & Developmental Biology
Purity
99.33% (May vary between batches)
Solubility
DMSO:200 mg/mL (349.27 mM) ; H2O:80 mg/mL (139.71 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (8.73 mM)
Molecular Weight
572.62
Storage Conditions
Keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
250063-ML490 100 µL
PHGDH (Phosphoglycerate Dehydrogenase, 3-PGDH, 3PGDH, MGC3017, PDG, PGAD, PGD, PGDH, SERA) (MaxLight 490)
Sign In for Pricing
View Details